Frontiers in Diabetic Macular Edema: Addressing Health Disparities and Other Barriers to Optimal Outcomes

Frontiers in Diabetic Macular Edema: Addressing Health Disparities and Other Barriers to Optimal Outcomes

Frontiers in Diabetic Macular Edema: Addressing Health Disparities and Other Barriers to Optimal Outcomes
RestartResume

Tune in to hear how Drs. Vivian Fonseca and Rishi Singh are identifying and breaking through barriers to improve diabetes-related vision outcomes.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Vivian Fonseca, MD
    Professor of Medicine and Pharmacology
    Assistant Dean for Clinical Research
    Tullis Tulane Alumni Chair in Diabetes
    Chief, Section of Endocrinology
    Tulane University Health Sciences Center

    Contracted Research Support: Grants from Fractyl
    Honoraria for Consulting and Lectures: Takeda, Novo Nordisk, Sanofi- Aventis, Bayer Abbott, Astra- Zeneca, Intarcia, Asahi
    Stock Options: Mellitus Health, BRAVO4Health
    Stock: Amgen

    Faculty:
    Rishi P. Singh, MD
    Staff Physician, Cole Eye Institute
    Cleveland Clinic Foundation
    Professor of Ophthalmology
    Lerner College of Medicine, Case Western Reserve University
    Cleveland, OH

    Consulting Fees: Alcon, Genentech, Regeneron, Novartis, Bausch and Lomb, Gyroscope
    Contracted Research: Apellis, Graybug, Aerie

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain why the risk of DME-related blindness is heightened in vulnerable populations impacted by gaps in health equity
    • Describe the barriers that may prevent the optimization of treatment for DME in vulnerable populations and strategies to overcome them
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmic surgeons, ophthalmologists, diabetologists, endocrinologists, primary care physicians, optometrists, and retina specialists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Register

We’re glad to see you’re enjoying Eye Health Academy…
but how about a more personalized experience?

Register for free